Delphix Accelerates Growth, Profitability for Second Consecutive Year at Scale
Data Security, Compliance Drive Urgent Adoption of Delphix DevOps Test Data Management Platform
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Delphix, the industry leader in DevOps test data management (TDM), today announced closing fiscal year 2022 with a second consecutive year of accelerated revenue growth and profitability at a scale well over $100M in annual recurring revenue (ARR).
With increasing activity from hostile nation states and ransomware gangs, companies around the world need a solution to automate and secure test data for enterprise applications. As a result, the company also reported 36% faster year-over-year growth of its large, enterprise customer base driven by increasing data risks.
Delphix’s growth comes as companies around the world continue to invest in innovative DevOps solutions to accelerate application delivery, modernize legacy infrastructure, and move applications across the multicloud. Delphix offers the only DevOps TDM platform that automates the delivery of secure, compliant data for test and development, enabling up to 10x faster innovation.
“Enterprise applications all need test data for fast, quality releases,” said Jedidiah Yueh, Delphix Founder and CEO. “But test data has traditionally been slow, complex, and filled with risk. Delphix helps companies like Banco Carrefour, The University of Manchester, and BNP Paribas release applications quickly while improving data security and compliance.”
Banco Carrefour in Brazil utilizes the Delphix DevOps Data Platform to accelerate application releases while ensuring data security and compliance with privacy regulations such as Brazil’s General Data Protection Law (LGPD). Delphix empowers development teams with 320x faster data availability for financial reporting and analytics, enables faster application releases, and helps save 70% on storage.
Delphix delivers an innovative API-first data platform that transforms application delivery with comprehensive data controls. By automating data delivery into test environments, Delphix helps software developers innovate faster while reducing compliance and security risk.
Delphix also helps companies recover faster from ransomware attacks by continuously protecting data and making historical data immutable.
“We selected Delphix, because we like the technology as a tool to move data efficiently from one place to another, to reconstruct, to travel to the past,” said Yves Caseau, Group Chief Digital & Information Officer at Michelin. “If we look at what we've done, we used Delphix to move data from our Exadata server legacy to community Linux servers to get more scalability and lower cost.”
“We are also using Delphix as a way to accelerate innovation and set up new test and development environments faster. We can get all the appropriate data very fast with a few pointers and a few clicks and have a virtual transfer of the data as opposed to a physical one,” Caseau added.
Test data management is a critical component of application development but is often slow and manual. The Delphix DevOps Data Platform enables teams to create, manage, and automate hybrid cloud-based data environments to support CI/CD pipelines and train AI/ML algorithms.
"Compliant test data is the lifeblood of DevOps and ensuring continuous access to it is key for enterprises to accelerate application delivery," said Jim Mercer, Research Director of DevOps and DevSecOps at IDC. "With digital transformation becoming increasingly essential for enterprises to compete across today's marketplaces, we continue to see the need for modern TDM solutions across multiple industries."
Delphix Growth Highlights
- Accelerated growth and profitability over the last two years at a scale greater than $100M of annual recurring revenues.
- Expanded large enterprise customer base:
- Increased the number of new enterprise customers won year-over-year by 36%.
- Broadened global customer base with large brands such as Banco Carrefour, Choice Hotels, Michelin, and Molina Healthcare.
- Appointed new additions to the global leadership team, including:
- Robert Stevenson, VP of Japan Operations, to expand Delphix in APAC.
- Josh Harbert, Chief Marketing Officer, who brings decades of experience to scale Delphix’s global marketing programs and amplify product and brand awareness.
- Pritesh Parekh, Chief Trust & Security Officer, VP of Engineering, who adds proven DevOps and security expertise.
- Steve Barrett, Senior Vice President of International Operations, who leads revenue operations for both EMEA and APJ.
- Tammi Warfield, Chief Customer Officer, a former Microsoft executive who drives customer success by helping customers realize business value.
Delphix also introduced multiple innovations across the company’s product offerings in last fiscal year, including:
- Continuous Vault, a ransomware-specific capability that boosts the Delphix platform’s data isolation capabilities and strengthens data protection for enterprises.
- Data Compliance Capabilities for Salesforce Customers, which helps Salesforce customers protect data privacy and security, while unlocking the value in Salesforce data across clouds and on premises data centers.
- Data Control Tower, which provides a single point of control for API-driven test data automation across development pipelines at scale.
- Masking Algorithms for Continuous Compliance, which deliver new, industry-leading algorithms for masking sensitive data along with an SDK enabling the development and automation of custom algorithms.
- SAP-certified integration with SAP NetWeaver® and SAP S/4HANA®, which allows businesses to use Delphix to mask and automatically deliver efficient, virtualized SAP data via APIs.
Delphix is the industry leader for DevOps test data management.
Businesses need to transform application delivery but struggle to balance speed with data security and compliance. Our DevOps Data Platform automates data security, while rapidly deploying test data to accelerate application releases. With Delphix, customers modernize applications, adopt multi-cloud, achieve CI/CD, and recover from downtime events such as ransomware up to 2x faster.
Leading companies, including Choice Hotels, Banco Carrefour, and Fannie Mae, use Delphix to accelerate digital transformation and enable zero trust data management. Visit us at www.delphix.com. Follow us on LinkedIn, Twitter, and Facebook.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release
Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed
Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release
Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral
Share Buyback Transaction Details May 12 – May 18, 202219.5.2022 10:00:00 CEST | Press release
Share Buyback Transaction Details May 12 – May 18, 2022 May 19, 2022 - Wolters Kluwer today reports that it has repurchased 118,000 of its own ordinary shares in the period from May 12, 2022, up to and including May 18, 2022, for €11.0 million and at an average share price of €92.92. These repurchases are part of the share buyback program announced on February 23, 2022, under which we intend to repurchase shares for up to €600 million during 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€) 2022 to date 2,573,464 238.4 92.64 For the period starting May 5, 2022, up to and including August 1, 2022, we have engaged a third party to execute €140 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are add
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)19.5.2022 09:01:00 CEST | Press release
Dante Labs is a Global Leader in Genomics and Precision MedicineMainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC). Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to co
Regarding the approval of the key financial performance indicators for AB Klaipėdos nafta for the period of 2022-202419.5.2022 08:22:29 CEST | Press release
AB Klaipėdos nafta (hereinafter – the Company) hereby informs that the Government of the Republic of Lithuania on 18 May 2022 adopted the resolution No. 509 “Regarding the approval of the key financial performance indicators for state-owned enterprises for the period of 2022-2024”, which establishes the following performance indicators for the Company: Indicator202220232024Average annual adjusted EBITDA* Period 2022–2024 ≥ EUR 33.9 millionAnnual financial debt to equity ratio Period 2022–2024 limit 1.7–3.2 times * EBITDA less adjustment (temporary regulatory differences, temporary fluctuations in the fair value of financial derivatives, results from disposal or revaluation of non-current assets, compensations received for previous periods, other non-typical corrections). Mindaugas Kvekšas, Chief Financial Officer, +370 46 391772